What ALS is
Amyotrophic lateral sclerosis (ALS), usually called motor neuron disease in the UK, causes progressive damage to the nerve cells that control movement, speech, swallowing and breathing. Cannabis research has examined symptom reports and animal models, but not a controlled treatment trial in people with ALS.
Cannabis research on ALS (motor neuron disease)
The ALSUntangled group reviewed cannabis in 2012. Its evidence appraisal found a biological rationale and possible relevance to symptoms such as pain, spasticity, appetite and sleep, but very limited clinical evidence. It did not establish that cannabis changes the course of ALS.
Amtmann and colleagues surveyed people with ALS who used cannabis. Participants described symptom experiences and reasons for use. A survey can show what patients report, but it has no placebo group and cannot separate a treatment effect from expectations, product differences or other care.
Weydt and colleagues tested cannabinol in SOD1 transgenic mice. Cannabinol delayed symptom onset but did not extend survival. That result concerns one compound in one animal model; it does not show benefit in people.
Together, the studies provide a rationale for research, not evidence of a human treatment effect.
Compounds studied for ALS (motor neuron disease)
CBN is the only cannabinoid in this register tested directly in an ALS model. The mouse study found later symptom onset without longer survival.
THC and CBD appear in broader discussion of pain, spasticity and neuroinflammation, but the cited ALS studies do not establish either compound as an ALS treatment.
No condition-specific terpene study appears in the ALS register, so terpene effects are not presented as ALS evidence.
Limits of the evidence for ALS (motor neuron disease)
The register contains an evidence appraisal, a patient survey and a mouse study. There is no randomised human trial and no study showing slower disease progression or longer survival in people with ALS.
Symptom findings from other conditions cannot be assumed to apply to ALS, where swallowing and respiratory problems materially change treatment and route considerations. Human trials would need a defined preparation, relevant symptom outcomes and respiratory monitoring.
Related conditions
- MS spasticity: licensed-product and guideline evidence
- Parkinson’s disease: randomised and observational studies
- Palliative care: symptom research in advanced illness
Read next
Sources
1. The ALSUntangled Group. ALSUntangled No. 16: Cannabis. Amyotrophic Lateral Sclerosis. 2012;13(4):400-404. Study record
2. Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT. Survey of cannabis use in patients with amyotrophic lateral sclerosis. American Journal of Hospice and Palliative Medicine. 2004;21(2):95-104. Study record
3. Weydt P, Hong S, Witting A, et al. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2005;6(3):182-184. Study record
